Twitter Facebook LinkedIn YouTube

Medical Device Innovator OxySure Systems (OTCQB: OXYS) Summarizes Recent Corporate Activities

Video Platform Video Management Video Solutions Video Player

OxySure Systems (OTCQB: OXYS) a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology, has recent activities summarized in video by

Additional Information:

Company: OxySure Systems
Stock Symbol: OTCQB: OXYS
Date Published: Feb 18, 2014
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for

OxySure Systems, symbol OXYS on the OTCQB, is a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology.

The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems.

The OxySure Model 615, available over the counter and FDA approved requiring no prescription, releases medically pure oxygen when two inert powders within its single use cartridge are combined, thereby eliminating the need for storage cylinders or tanks.

Users simply plug in the mask, turn the knob, and place the mask over the nose and mouth.

The OxySure Model 615 is sold through more than 40 distributors in the US and overseas distributors in Australia and New Zealand, the UK, Brazil, Chile, and Hong Kong.

OxySure’s products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need, such as:
- public and private locations where medical emergencies can occur
- individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to the arrival of medical care, and
- those requiring immediate protection and escape from oxygen-deficient situations in industrial, mining, military, or other environments deemed “Immediately Dangerous to Life or Health”

The OxySure Model 615 is a perfect companion product to external automated defibrillators, of which there are 3 million units installed worldwide. In the long term, Model 615 promises to be like a fire extinguisher, of which there are more than 100 million units installed in the US alone.

OxySure has had a very active January, which started with the closing of a $750,000 private placement with accredited institutional investors.

The company also converted approximately $968,000 of debt into restricted common shares with conversion prices ranging from $0.76 to $1.50 per share.

Julian Ross, Chairman & CEO stated, “The debt conversions demonstrate significant progress in our strategy to strengthen our balance sheet, especially as we set our sights on the goal of meeting the criteria for an uplisting to a senior exchange in the foreseeable future. As a result of these conversions, we are entering 2014 with a significantly improved financial profile.”

Revenues for the 9 months ended September 30, 2013 were $1.3 million, an increase of 550% versus the $200,000 reported in the same period in the previous year, with gross margins widening by 37%.

New York-based Taglich Brothers recently updated their speculative buy recommendation, reiterating their 12-mointh target price of $2.10, a premium of 163% to the $0.80 price the day the report was issued.

Analyst Juan Noble stated, “We project a revenue ramp from $2 million in 2013 to $4.9 million in 2015. As the OxySure Model 615 gains traction, revenue should increase to $18 million by 2017. That long-term revenue estimate is based on moderate acceptance of the Model 615, mainly as a companion to automatic external defibrillators.”

The company currently trades at $0.67, well below the $2.10 target price, and with 24.2 million shares outstanding, the company is capitalized at $16.2 million.

For more information about OxySure, or to obtain a copy of the research report, please visit the company’s website or contact the investor relations department at 972-294-6461 or by email at

Investor relations is handled by Christian Hansen of Maximum Performance Advisors, who can be reached at 858-381-4677 or by email at

I’m Samantha Deutscher for
For more video news, and to view our disclaimer, be sure to visit our website
This video is for information purposes only and it is not a recommendation to buy or sell any securities.